AKAP9 involvement in cancer disease was first mentioned in thyroid cancers, where chromatin rearrangement (paracentric inversion of chromosome 7q) results in the formation of an AKAP9-BRAF fusion protein that affects B-Raf action and constitutively activates the MAPK pathway [35]. This evidence concerns the gene BRAF and thyroid gland carcinoma.